Reason for request
The actual benefit of BETESIL 2.25 mg medicated plaster in the Marketing Authorisation indication is substantial.
Clinical Added Value
|no clinical added value||
BETESIL 2.25 mg medicated plaster does not offer any improvement in actual benefit (non-existent IAB V) in the treatment strategy for psoriasis and other inflammatory skin disorders that do not respond to less potent corticosteroids.